aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
P/E ratio for aTyr Pharma, Inc. (LIFE)
P/E ratio as of 2023: -1.50
According to aTyr Pharma, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.50. At the end of 2022 the company had a P/E ratio of -1.41.
P/E ratio history for aTyr Pharma, Inc. from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.50 |
| 2022 | -1.41 |
| 2021 | -4.39 |
| 2020 | -2.38 |
| 2019 | -0.63 |
| 2018 | -0.43 |
| 2017 | -1.87 |
| 2016 | -0.88 |
| 2015 | -3.25 |
| 2014 | -6.18 |
| 2013 | -7.52 |
| 2012 | 0.00 |